Article Text

Download PDFPDF

#599 Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: may bevacizumab add something? a large retrospective study
Free
  1. Raffaella Ergasti1,
  2. Laura Vertechy1,
  3. Serena Maria Boccia1,
  4. Luigi Congedo1,
  5. Filippo Maria Capomacchia1,
  6. Mariagrazia Distefano1,
  7. Giovanni Scambia1,2,
  8. Anna Fagotti1,2 and
  9. Claudia Marchetti1,2
  1. 1Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
  2. 2Università Cattolica del Sacro Cuore, Rome, Italy

Abstract

Introduction/Background Few data are available on Bevacizumab in neoadjuvant chemotherapy (NACT) setting for High Grade Serous ovarian Cancer (HGSC) patients. We investigate the effect of Bevacizumab addition to standard NACT regimen (Carboplatin and Paclitaxel) after Interval Debulking Surgery (IDS) failure following the first 3 NACT cycles.

Methodology This is a retrospective, single-centre study enrolling FIGO stage IIIC-IV HGSC patients (regardless of BRCA status) still considered unresectable after 3 cycles of NACT. Main inclusion criteria were: ECOG 0, age ranging from 40 to 75 years old, no contraindications to Bevacizumab administration. Patients were stratified whether they added Bevacizumab from cycle 4 to 6 (CPB group) or not (CP group). Primary endpoint was the cytoreduction rate after 6 cycles (delayed IDS).

Results From 2017 to 2021, 58 (23%) patients received neoadjuvant Bevacizumab (CPB), and 190 (77%) did not (CP). Only 118 (48%) women received delayed IDS: 31 in the CBP group (46%) and 87 (53%) in the CP one (p=0.38); complete gross resection was achieved in 26 (84%) and 77 (88%) patients, respectively (p=0.72). We did not find any difference in terms of severe early postoperative complications (8% for the CP group and 10% for the CPB one, p=0.069). Median Overall Survival (OS) was not significantly different between the two groups for those patients undergoing delayed IDS (not reached in the CPB and 38 months in the CP group, p=0.55). Conversely, among 130 (52%) patients still unresectable after 6 cycles, Bevacizumab had a significant effect on the CPB group’s median OS compared to the CP one (not reached vs 18 months, p=0.015).

Conclusion The use of Bevacizumab in neoadjuvant setting does not seem to increase the delayed IDS rate, nonetheless it prolongs OS for those patients persisting unsuitable for surgery. Thus, its administration may be an option in selected patients after failure of early IDS.

Disclosures None

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.